AIM
BRTX icon

Axiom Investment Management’s BioRestorative Therapies BRTX Stock Holding History

Axiom Investment Management’s Portfolio BRTX Stock Details BRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1
Closed – – 132
2022
Q3 		$0 Buy
+1
New +$3 ﹤0.01% 419

Other funds holding BRTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
AC
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Axiom Investment Management's BRTX Position: Q4 2022 in Review

Axiom Investment Management sold out of BioRestorative Therapies (BRTX) in Q4 2022, closing a stake of 1 share.

Axiom Investment Management first reported a position in BRTX in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 15 funds tracked by Wall St. Rank hold BRTX as of Q4 2022.

  • Axiom Investment Management reported no remaining BioRestorative Therapies position as of Q4 2022 after selling out during the quarter.
  • Axiom Investment Management sold 1 BioRestorative Therapies share in Q4 2022.
  • Axiom Investment Management first reported a position in BioRestorative Therapies in Q3 2022 and held it in 1 quarter.
  • Axiom Investment Management's BioRestorative Therapies position peaked at $0 in Q3 2022.
  • 15 funds tracked by Wall St. Rank held BioRestorative Therapies as of Q4 2022.

Based on Axiom Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.